In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 48 days of free consultation

 

Laughter therapy increases functional capacity in patients with coronary artery disease: a randomized clinical trial

Session Poster Session 1

Speaker Associate Professor Ricardo Stein

Congress : EuroPrevent 2019

  • Topic : preventive cardiology
  • Sub-topic : Cardiovascular Rehabilitation
  • Session type : Poster Session
  • FP Number : P299

Authors : R Stein (Porto Alegre,BR), A Donelli Da Silveira (Porto Alegre,BR), D Do Santos Macedo (Porto Alegre,BR), J Beust De Lima (Porto Alegre,BR), J Maia Delfino (Porto Alegre,BR), L Tolfo Franzoni (Porto Alegre,BR), M Aurelio Lumertz Saffi (Porto Alegre,BR), RM Nery (Porto Alegre,BR)

15 views

Authors:
R Stein1 , A Donelli Da Silveira1 , D Do Santos Macedo1 , J Beust De Lima1 , J Maia Delfino1 , L Tolfo Franzoni1 , M Aurelio Lumertz Saffi2 , RM Nery2 , 1Federal University of Rio Grande do Sul - Porto Alegre - Brazil , 2Hospital de Clínicas de Porto Alegre - Porto Alegre - Brazil ,

Citation:

Background: The impact of a laugher therapy cardiac rehabilitation (LTRehab) program for patients with coronary artery disease (CAD) has yet to be assessed. 

Purpose: To evaluate the potential effect of LTRehab (comedy sessions) on functional capacity in stable CAD patients

Methods: A single-blind randomized clinical trial (RCT) was conducted. The researchers who performed the tests were blinded to group allocation. Peak oxygen uptake (VO2peak) was measured by a maximal cardiopulmonary exercise testing (CPET). Patients allocated to LTRehab (n=12) watched two weekly sessions of a self-selected comedy and the control group (n=12) watched two weekly sessions of a neutral documentary (24 movies per group). ANCOVA was performed to estimate VO2peak main effect adjusted to baseline values.

Results: Twenty-four CAD individuals (70% male; 64±10 years) were included. After 12 weeks of intervention, VO2peak increased significantly in LTRehab group (10%) compared to control (19.4 ± 2.9 to 21.4 ± 3.4vs 23.2 ± 6.3 to 22.2 ± 7.1 mL.kg-1.min-1, pre and post intervention, respectively; P=0.005). All CPET reached maximal criteria (R>1.10). 

Conclusion: This is the first RCT to evaluate LTRehab in CAD patients. It was associated with an increase in VO2peak and may constitute an effective form of cardiac rehabilitation in this patient population.

This content is currently on FREE ACCESS, enjoy another 48 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are